Clinical development of HER3-targeting monoclonal antibodies: Perils and progress
Author:
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference127 articles.
1. First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC);Alsina;J Clin Oncol,2017
2. Association of ErbB/HER biomarkers with antitumor activity of the anti-ErbB3/HER3 monoclonal antibody KTN3379 in SCCHN;Alvarado;Cancer Res,2015
3. A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors;Arnedos;J Clin Oncol,2013
4. A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors;Bauer;J Clin Oncol,2015
5. MM-111-a novel bispecific antibody targeting HER-2/HER-3 Z heterodimer: safety and tolerability in a first-in human phase I/II study in patients with refractory HER2-positive (HER-2+) cancers;Beeram;Cancer Res,2010
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. HER3 receptor and its role in the therapeutic management of metastatic breast cancer;Journal of Translational Medicine;2024-07-17
2. Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future;Medicinal Research Reviews;2024-06-17
3. HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs;Cancer Drug Resistance;2024-04-29
4. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors;Journal of Translational Medicine;2024-04-17
5. The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer;Frontiers in Physiology;2024-03-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3